- Home
- PAA vs EXEL Comparison
PAA vs EXEL Comparison
Compare PAA & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAA | EXEL |
|---|---|---|
| Founded | 1981 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | PAA | EXEL |
|---|---|---|
| Price | $17.72 | $45.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 24 |
| Target Price | $20.44 | ★ $45.18 |
| AVG Volume (30 Days) | ★ 3.0M | 2.8M |
| Earning Date | 02-06-2026 | 02-10-2026 |
| Dividend Yield | ★ 8.66% | N/A |
| EPS Growth | 8.03 | ★ 53.55 |
| EPS | 1.21 | ★ 2.38 |
| Revenue | ★ $46,917,000,000.00 | $2,288,218,000.00 |
| Revenue This Year | N/A | $9.84 |
| Revenue Next Year | $3.43 | $11.92 |
| P/E Ratio | ★ $14.46 | $18.64 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $15.58 | $31.90 |
| 52 Week High | $21.00 | $49.62 |
Technical Indicators
Market Signals| Indicator | PAA | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 68.00 |
| Support Level | $17.53 | $40.83 |
| Resistance Level | $17.89 | $42.09 |
| Average True Range (ATR) | 0.26 | 1.23 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 50.77 | 94.52 |
Price Performance
Historical ComparisonAbout PAA Plains All American Pipeline L.P.
Plains All American Pipeline LP through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and barges or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.